-
Study aim
-
etermining the effect of Reuteflor probiotic on the quality of life and reduction of seizures in treatment-resistant epilepsy patients in pediatric neurology clinics of Urmia University of Medical Sciences.
-
Design
-
The samples under investigation in the present study are 75 children with epilepsy resistant to treatment with an age range of 3 to 18 years old that referred to pediatric clinics of Urmia University of Medical Sciences, who were selected consecutively and available according to the inclusion criteria
-
Settings and conduct
-
The present study is an intervention study of before and after type. The place of study is pediatric neurology clinics of Urmia University of Medical Sciences
-
Participants/Inclusion and exclusion criteria
-
The criteria for inclusion in the study were all drug-resistant epilepsy patients between the ages of 3 and 18 year old.
Exclusion criteria : the development of serious complications following the use of drugs, lack of satisfaction with the continuation of the study,
Non-epileptic seizures, change in the dose and type of anti-epileptic drugs in the last 30 days, probiotic consumption in the last 30 days, insufficiency Renal or hepatic, lactose intolerance, celiac disease, long-term antibiotic use and life expectancy of less than 1 year, as well as the presence of progressive neurodegenerative disease, the presence of any psychiatric disorder, and the receipt of relevant drugs according to the parents' opinion.
-
Intervention groups
-
In the present study, the intervention is the prescription of probiotic medicine.
The probiotic under investigation, is Reuteflor that contains lyophilized lactobacillus reuteri bacteria with a daily dose of one sachet will be given.
-
Main outcome variables
-
The average number of convulsions of patients with resistant epilepsy 3 months after the start of probiotic and before the start of the intervention is different.